



30 **Abstract**

31 **Background**

32 High throughput 16S rRNA gene sequencing and enhanced culture methods (e.g., expanded  
33 quantitative urine culture, EQUUC) have established the existence of the human bladder  
34 microbiome. We aim to test the hypothesis that the bladder environment of patients with chronic  
35 kidney disease (CKD) differs from that of unaffected controls with associated consequences for  
36 the composition of the bladder microbiome.

37 **Methods and Materials**

38 Females (n=66) and males (n=66) diagnosed with CKD and age-BMI-matched healthy control  
39 (HC) females (n=22) and males (n=22) were recruited. Transurethral catheterized urine was  
40 collected for 16S rRNA gene sequencing and Expanded Quantitative Urine Culture (EQUUC).  
41 Fecal samples also were sequenced. Urinary analysis, kidney function and serum cytokines were  
42 examined.

43 **Results**

44 Bladder microbiomes of CKD females and males versus HC females and males differed  
45 (FDR<0.05); however, the difference was more obvious in females. In CKD females, sequencing  
46 revealed depletion of 5 genera, including *Lactobacillus*, and enrichment of 14 genera, including  
47 *Escherichia/Shigella*, *Bifidobacterium*, and several clostridial genera (FDR<0.05), while EQUUC  
48 detected increased *Escherichia* and decreased *Lactobacillus* CKDB(P<0.05). *Escherichia-Shigella*  
49 was positively, whereas *Lactobacillus* was negatively, associated with CKDB-female serum  
50 creatinine ( $r=0.285$ ,  $P=0.020$ ;  $r=-0.337$ ,  $P=0.006$ , respectively). *Lactobacillus* was positively  
51 associated with eGFR ( $r=0.251$ ,  $P=0.042$ ). Some CKD-related serum cytokines were negatively  
52 associated with clostridial genera. In contrast, the fecal microbiomes of CKD and HC females and  
53 males did not significantly differ in bacterial diversity or composition. However, bladder and fecal  
54 microbiomes of CKD females resembled each other more than those of controls, as assessed by  
55 the Bray-Curtis Dissimilarity Index (FDR<0.05).

56 **Conclusions**

57 CKD bladder microbiomes were dysbiotic, which was more obvious in females. This dysbiosis  
58 was associated with kidney damage severity and dysregulation of serum cytokines. The increased

59 similarity between bladder and fecal microbiomes of CKD females suggests possible  
60 “gut-leakage.”

61 **Key words**

62 bladder; chronic kidney disease; cytokine; fecal microbiome; kidney function; microbiome

63 **1 Introduction**

64 Chronic kidney disease (CKD) is a non-communicable disease that affects more than 10% of  
65 the general population worldwide[1]. It is a progressive disease that over time leads to irreversible  
66 nephron loss and kidney failure. However, CKD is uncured by current therapies, possibly due to  
67 its unclear pathology. Previous studies found that microbial dysbiosis in human gut and blood is  
68 associated with CKD[2, 3], and crosstalk between host and microbiome is pathophysiologically  
69 relevant to CKD[2, 3].

70 The human bladder harbors its own microbial community[4-8]. Most studies have explored  
71 associations between the microbiomes of urine samples obtained by transurethral catheter (bladder)  
72 or midstream void (urogenital) and urinary tract disorders, such as urinary stone disease[9],  
73 urinary tract infection (UTI)[10], and bladder cancer[11]. One study assessed the urogenital  
74 microbiome in CKD patients and found it to be extremely diverse with greater diversity associated  
75 with estimated glomerular filtration rate (eGFR). However, this study did not include controls and  
76 analyzed voided urine samples[12], which often contains microbes from both the urinary and  
77 genital tracts[13, 14].

78 Kidneys are a major site for elimination of many cytokines. The delicate equilibrium of  
79 proinflammatory cytokines and their inhibitors is dysregulated in CKD[15], and associated with  
80 gut dysbiosis in CKD[16, 17]. For example, the dysregulation of tumor necrosis factor (TNF- $\alpha$ )  
81 and interleukin-6 (IL-6) is associated with gut dysbiosis in CKD[16, 17].

82 With mounting evidence of an interaction between gut microbiome and kidney function, some  
83 researchers have proposed a gut-kidney axis[18, 19]. However, these researchers ignored the  
84 possible existence of microbiomes in the urinary tract[20, 21]. Given that microbes are exquisitely  
85 sensitive to their environments and are known to interact with their niches, we hypothesize that (1)  
86 CKD patients have a dysbiotic bladder microbiome, (2) the bladder microbiome distinguishes  
87 CKD patients better than the fecal microbiome, and (3) the bladder microbiome is associated with  
88 serum cytokines.

89 **2 Materials and methods**

90 **2.1 Study participant recruitment**

91 Participants were recruited from July 1<sup>st</sup> 2018 to March 30<sup>th</sup> 2020. **Figure S1** displays the study



92 design, including participant recruitment, methods, and objectives. Diagnostic criteria of CKD  
93 included decreased eGFR [ $<60$  mL/min/1.73m<sup>2</sup> or evidence of kidney damage, such as  
94 albuminuria (albumin excretion rate  $\geq 30$  mg/24 h; urinary albumin creatinine ratio [UACR]  $\geq 30$   
95 mg/g], urine sediment abnormalities, electrolyte and other abnormalities due to tubular disorders,  
96 abnormalities detected by histology, and/or structural abnormalities detected by imaging or history  
97 of kidney transplantation[22]. CKD patients undergoing hemodialysis were excluded.  
98 Asymptomatic controls (“healthy” controls, HC) were recruited if they had an eGFR $\geq 90$   
99 ml/min/1.73m<sup>2</sup> and were free of current renal damage, a history of liver disease, cancer, diabetes,  
100 hypertension, and hyperlipidemia. After recruitment, HC subjects were excluded if they had an  
101 indicator of urinary tract infection (UTI) by urinalysis, such as  $>5$  WBCs/HPF,  $>3$  RBCs/HPF,  
102 positive urine nitrites, positive leucocyte esterase, positive occult, positive protein, and abnormal  
103 values of diabetes, hypertension, hyperlipidemia. Any participant with acute intercurrent disease  
104 or infection, diarrhea, kidney transplantation, pregnancy, breastfeeding was excluded. Those who  
105 used antibiotics, probiotics or immunosuppressive drugs within 30 days before enrollment also  
106 were excluded.

## 107 ***2.2 Urine collection and storage***

108 Bladder urine samples were collected by transurethral catheterization and stored as reported  
109 previously[23]. Before catheter insertion, 5% iodophor was applied to disinfect the genital and  
110 perineal areas. Fifty mL urine were obtained and separated into three portions (i.e., 30 mL, 5 mL  
111 and 15 mL) that were used for 16S rRNA gene sequencing, Expanded Quantitative Urine Culture  
112 (EQUC) and clinical urinary analysis[4], respectively. All samples were processed in a biosafety  
113 cabinet. Samples for 16S rRNA gene sequencing and EQUC were placed in sterile, DNA- and  
114 enzyme-free centrifuge tubes. Samples for 16S rRNA gene sequencing were stored at  $-80^{\circ}\text{C}$   
115 refrigerator within 15 mins after collection. Samples for EQUC were placed in an insulated sterile  
116 container, immediately cooled on ice, and transferred to the research personnel within 4 hours.

## 117 ***2.3 Expanded Quantitative Bladder Urine Culture***

118 Methods for EQUC were modified according to previous studies[6, 24]. 0.1 mL of catheterized  
119 bladder urine was inoculated onto BAP, chocolate and colistin, as well as nalidixic acid agars  
120 (Kemajia inc., Shanghai, China), streaked for quantification, and incubated in 5% CO<sub>2</sub> at  $35^{\circ}\text{C}$  for

121 48h. Next, 0.1 mL of urine was inoculated onto two CDC anaerobe 5% sheep blood agar plates  
122 and incubated in an anaerobic incubator with a Campy gas mixture (5% O<sub>2</sub>, 10% CO<sub>2</sub>, 85% N<sub>2</sub>) at  
123 35°C for 5 days. 1.0 mL of urine was placed in thioglycolate medium and incubated aerobically at  
124 35°C for 5 days. If growth was visually detected in the thioglycolate medium, the medium was  
125 mixed, and 0.01 mL of urine was plated on BAP and CDC anaerobe 5% sheep blood agars for  
126 isolation and incubated aerobically and anaerobically at 35°C for 48h. Each morphologically  
127 distinct colony type was isolated on a different plate of the same media to prepare a pure culture  
128 that was used for identification, as described below.

#### 129 ***2.4 16S rRNA gene sequencing***

130 Bacterial DNA isolation from urine was described previously[6, 24]. The quantity and quality  
131 of the extracted DNA was measured using a NanoDrop ND-1000 spectrophotometer (Thermo  
132 Fisher Scientific, Waltham, MA, USA) and agarose gel electrophoresis. Using the isolated DNA as  
133 the template, the bacterial 16S rRNA V3-V4 region was PCR-amplified for 32 cycles using  
134 universal primers 338F and 806R. The resultant PCR amplicons were purified with Agencourt  
135 AMPure XP Beads (Beckman Coulter, Indianapolis, IN, USA) and quantified using the PicoGreen  
136 dsDNA Assay Kit (Invitrogen, Carlsbad, CA, USA). Amplicon pools were prepared for  
137 sequencing, and the size and quantity of the amplicon library were assessed using an Agilent 2100  
138 Bioanalyzer (Agilent, Santa Clara, MA, USA) and Library Quantification Kit for Illumina (Kapa  
139 Biosciences, Woburn, MA, USA), respectively. The libraries were sequenced using the NovaSeq  
140 6000 platform. As urines are low-biomass samples, they were sequenced in duplicate for  
141 reproducibility. When the Bray-Curtis dissimilarity of the duplicated urinary microbiome samples  
142 was above 0.3[25], they were re-sequenced. If their Bray-Curtis dissimilarity remained above  
143 0.3[25], they were removed from further analysis. Six negative controls (2 without urine, 2  
144 without bacterial DNA, and 2 without PCR product) also were sequenced.

#### 145 ***2.5 Bioinformatic analysis of 16S rRNA gene sequencing data***

146 Raw reads of the 16S rRNA gene sequences were trimmed using Cutadapt  
147 (cutadapt.readthedocs.io) to remove barcodes and adaptors. The overlapping paired-end reads  
148 were merged into a longer tag using FLASH (v1.2.8). Reads were quality trimmed using fdtrim  
149 (v0.94) from the 3' end to remove bases with low-quality scores. Reads shorter than 100bp, with

150 more than 5% Ns, or with an average quality below 20 were discarded. Chimeras were removed  
151 using Vsearch (v2.3.4). QIIME2 was used to process the clean reads to generate an ASV table, and  
152 taxonomy of microbes was identified using the Silva database (v138). Environmental  
153 contaminants of urine samples were removed as previously described[20]. Bacterial ASVs whose  
154 counts did not exceed five times the maximum number of counts in the negative controls were  
155 considered as contaminants and removed, as described[20]. We also manually removed bacteria  
156 that have been reported to be environmental contaminants from soil and water.

## 157 ***2.6 Identification of bacterial isolates***

### 158 ***2.6.1 16S rRNA gene sequencing of bacterial isolates***

159 Bacterial isolates purified as described above were harvested: if the colonies were large enough,  
160 a single colony was chosen; if not, then the plate was scraped. To the harvested bacteria, 200 $\mu$ L  
161 lysis buffer (Guhe, Hangzhou, China) was added and its DNA extracted using the method  
162 described above for 16S rRNA gene sequencing. Identification of the isolates was confirmed by  
163 partial sequencing of the 16S rRNA gene. Briefly, the 16S rRNA gene was amplified for 30 cycles  
164 by PCR with universal primers 27F and 1492R, which results in an amplicon of approximately  
165 1500 bp. PCR was performed in a DNA thermocycler (Thermo Scientific, USA) with PCR Premix  
166 (Ensure biologicals, Shanghai, China) in 50  $\mu$ L reaction mixtures. The resultant amplicons were  
167 sequenced with the ABI Prism<sup>TM</sup> Bigdye<sup>TM</sup> terminator cycle sequencing reaction kit (Applied  
168 Biosystems, USA) using the 27F and 1492R primer pair. The sequencing product was purified  
169 using the Millipore-Montage dye removal kit (Ensure Biologicals, Shanghai, China) and  
170 sequenced on an ABI 3730XL capillary DNA sequencer (Applied Biosystems, USA). For each run,  
171 negative controls containing water instead of template DNA were run in parallel. All sequencing  
172 procedures were performed by BGI (Shanghai, China). For taxonomic identification, a portion of  
173 the sequence was compared to sequences in GenBank public database  
174 (<http://www.ncbi.nlm.nih.gov/BLAST/>).

### 175 ***2.6.2 MALDI-TOF MS identification of bacterial isolates***

176 When a bacterial isolate could not be identified by 16S rRNA gene sequencing, we used  
177 Matrix-Assisted Laser Desorption Ionization-Time-Of-Flight Mass Spectrometry (MALDI-TOF  
178 MS), as described previously[4]. Briefly, a small portion of a single colony was overlaid with 1  $\mu$ L

179 of a saturated solution of alpha-cyano-4-hydroxycinnamic acid matrix in 50% acetonitrile and 2.5%  
180 trifluoroacetic acid (VITEK MSCHCA, bioMérieux), then air dried. *Escherichia coli* (ATCC 8739)  
181 was used for system calibration. Mass spectra were acquired using a VITEK MS Plus (bioMérieux,  
182 Marcy l'Etoile) and the bioMérieux VITEK MS (IVD Knowledgebase v.3.2) used to analyze a  
183 composite mass spectrum for accurate identification. A probability score between 60% and 99.9%  
184 was considered to be a high discrimination value and thus a reliable identification. A probability  
185 score <60% was considered to be a low discrimination identification. No identification resulted  
186 when either no match was found for the composite spectra, or the analysis did not obtain enough  
187 spectral peaks[26]. Isolates that yielded no identification results were redeposited on the target  
188 plate and reanalyzed.

### 189 **2.7 Other sample collection and processing**

190 Blood samples for assessment of renal function and serum cytokines were collected on the day  
191 of urinary sample collection. The Bio-Plex™ 200 System (Bio-Rad) and Bio-Plex Pro™ Human  
192 Cytokine Screening 48-plex Panel (Bio-Rad, California, USA) were used to detect serum  
193 cytokines. An aliquot of bladder urine (described above) was used for urinalysis. The 24-hour  
194 urine volume was collected one day prior to the day of bladder microbiome sample collection.  
195 Fecal samples were collected on the day of bladder urine sample collection. The participants were  
196 told to excrete their feces into a sterile container. A nurse then put 30 mg feces into a sterile tube  
197 using sterile technique and stored them at -80°C refrigerator within 15 mins of collection. DNA  
198 isolation and sequencing of fecal samples was the same as for the urine samples, except that they  
199 were sequenced only once, as we have found that Bray-Curtis values for feces samples are  
200 typically <0.3.

### 201 **2.8 Disease profiles assessment**

202 Participants' demographics data were collected during a face-to-face interview. Blood pressure  
203 and fasting blood glucose were assessed on the day of urine and fecal sample collection.

### 204 **2.9 Statistical analysis**

205 Pearson's Chi-square or Fisher's exact tests were used with categorical variables; Student's *t*  
206 test was used on normalized continuous variables and Wilcoxon rank-sum test was used on  
207 non-normal continuous variables. The *P*-value was adjusted for multiple comparisons using the

208 Benjamini–Hochberg (BH) false discovery rate (FDR). The significance threshold was set at an  
209 FDR-corrected value  $<0.05$ . Pearson correlation analysis was used to assess associations between  
210 variables, and the significance threshold was set at a P value  $<0.05$ .

### 211 **3 Results**

#### 212 **3.1 Participants**

213 Figure **S1** displays the process, including participant recruitment, methods, and study objectives.  
214 Briefly, we collected urine samples through sterilized catheter from 230 CKD patients and 176  
215 controls. All participants with catheterized urine (i.e., bladder) samples with bacterial DNA below  
216 the level of detection and control participants with abnormal urinalysis values were removed from  
217 downstream analysis. To ensure reproducibility, bladder urine samples were sequenced in  
218 duplicate, and participants whose samples were dissimilar (i.e., had a Bray-Curtis Dissimilarity  
219 score above 0.3) were removed from downstream analysis. From the remaining participants,  
220 age/BMI-matched CKD and HC males and females, resulting in 66 bladder urine samples from  
221 CKD males (CKDB-male) and 22 bladder samples from HC males (HCB-male) and 66 bladder  
222 samples from CKD females (CKDB-female) and 22 urine samples from HC females  
223 (HCB-female).

224 Compared to the HCB groups, both the male and female CKDB groups had higher rates of  
225 hypertension and diabetes, as well as higher rates of occult blood and cast in their urine (Fisher’s  
226 exact test,  $P<0.05$ ; **Table 1**). Although both male and female CKDB groups had higher levels of  
227 systolic blood pressure than those in controls, only female patients had a higher level of diastolic  
228 blood pressure than that in controls ( $t$ -test,  $P<0.05$ ; **Table 1**). Compared to HCB-males and  
229 HCB-females, the CKDB-males and CKDB-females had lower levels of eGFR and higher levels  
230 of serum creatinine, whereas the CKDB-males had a higher level of blood urea nitrogen and  
231 CKDB-females had a higher level of uric acid ( $t$ -test,  $P<0.05$ ; **Table 1**). No difference was found  
232 in the nutrient intake between the groups of CKD and HC ( $t$ -test,  $P<0.05$ , **Table S1**); thus, it was  
233 not considered to be a confounding factor in downstream analyses.

#### 234 **3.2 Bladder microbiomes are altered in CKD males and females**

235 As gender difference has been reported to impact the bladder microbiome in asymptomatic  
236 subjects and disease groups[27, 28], we wondered whether the bladder microbiome composition

237 of females and males differed between our CKDB and HCB groups. To test this, we performed  
238 principal-coordinate analysis (PCoA) of Bray-Curtis Dissimilarity indices for all microbial taxa  
239 (ASVs) present within and among the microbiomes of each group. As expected, the bladder  
240 microbiome of HCB-males and HCB-females was significantly separated ( $R^2=0.077$ ,  $FDR=0.002$ ;  
241 **Figure 1A**); the bladder microbiome of CKDB-males and CKDB-females was also separated but  
242 less so ( $R^2=0.017$ ,  $FDR=0.016$ ; **Figure 1A**). Since the bladder microbiome of males and females  
243 differed, further analyses were performed separately.

244 When comparing CKDB to HCB, we found that the bladder microbiomes of both males and  
245 females differed (PERMANOVA,  $R^2=0.033$ ,  $FDR=0.001$  and  $R^2=0.072$ ,  $FDR<0.001$ , respectively;  
246 **Figure 1A**). Hypertension, glucocorticoid levels, hypoglycemia and hypolipidemic agents were  
247 not confounding factors, as bladder microbiome of the medication users and gender-age matched  
248 non-users did not differ (PERMANOVA,  $FDR>0.05$ ; **Figure S2A-D**). The bladder microbiome of  
249 CKDB-males and CKDB-females was significantly more diverse than those of their respective  
250 HCB controls. For females, this was reflected in both the number ASVs (**Figure 1B**) and the Chao  
251 1 index, which estimate bacterial richness (Wilcoxon rank-sum test,  $FDR<0.001$ ; **Figure 1C**); for  
252 males, this increased richness was reflected only in the number of ASVs (**Figure 1B**). To assess  
253 whether bacterial richness was associated with renal function in CKDB females, we performed a  
254 Pearson correlation analysis between Chao1 and estimators of renal function (i.e., eGFR, serum  
255 creatinine, blood urea nitrogen, and serum uric acid), but no association was observed ( $P>0.05$ ).

### 256 **3.3 Bladder microbiome composition is altered in CKD patients**

257 Proteobacteria, Firmicutes, Actinobacteriota, Bacteroidota and Fusobacteriota were the 5 most  
258 abundant phyla in the bladder microbiomes of all 4 groups (**Figure 1D**). After correction for  
259 multiple testing, we observed no significant difference when we compared CKDB-males and  
260 HCB-males, and CKDB-females and HCB-females (Wilcoxon rank-sum test,  $FDR>0.05$ ; **Table**  
261 **S2 & S3**). Notably, at the genus level, both the CKDB-males and CKDB-females were enriched  
262 for *Escherichia-Shigella* (9.59% and 17.71%, respectively), and *Enterococcus* (3.34% and 5.63%  
263 respectively; **Figure 1E**). Next, we compared bacterial genera that accounted for  $>0.1\%$  of the  
264 total relative abundance in males and females. After correction for multiple testing, we observed  
265 no significant difference when we compared CKDB-males and HCB-males (Wilcoxon rank-sum

266 test,  $FDR > 0.05$ ; **Table S4**). In contrast, 19 genera differed significantly between CKDB-females  
267 and HCB-females (Wilcoxon rank-sum test,  $FDR < 0.05$ ; **Table S5**). Five genera were significantly  
268 less abundant in CKDB-females relative to HCB-females (Wilcoxon rank-sum test,  $FDR < 0.05$ ).  
269 These included one unknown genus in the family Comamonadaceae and the genera *Lactobacillus*,  
270 *Sphingobium*, *Sphingomonas*, and *Streptomyces* (**Table S5; Figure 2A**). Fourteen genera were  
271 significantly more abundant in CKDB-females, including *Escherichia-Shigella*. Others included  
272 *Agathobacter*, *Anoxybacillus*, *Bacteroides*, *Bifidobacterium*, *Blautia*, *Comamonas*,  
273 *Diaphorobacter*, [Eubacterium] coprostanoligenes group, *Faecalibacterium*, CAG-352 in the  
274 family Ruminococcaceae, *Sphingobacterium*, and *Subdoligranulum* (Wilcoxon rank-sum test,  
275  $FDR < 0.05$ ; **Table S5; Figure 2B**). Many of these taxa are members of the class Clostridia. As  
276 *Escherichia-Shigella* is one of most common causes of UTI[29, 30], and the participants with  
277 current UTI were excluded, we compared the abundance of *Escherichia-Shigella* between the  
278 age-matched CKDB-female urine samples with positive urinary leucocyte esterase and negative  
279 ones but there was no significant difference between the positive samples and negative ones  
280 ( $29.82 \pm 45.23$  vs.  $24.73 \pm 39.24$  (Wilcoxon rank-sum test,  $P = 0.781$ ,  $FDR = 0.814$ ). In addition, since  
281 *Lactobacillus* can impede *Escherichia* growth in the urinary tract[31], we performed Pearson  
282 correlation analysis to examine whether they were connected but there was no significant  
283 correlation ( $r = -0.221$ ,  $P = 0.075$ ).

284 To determine whether the detected sequences came from live bacteria, we performed EQU  
285 (**Table S6**), an enhanced culture method that vastly outperforms the standard clinical microbiology  
286 urine culture method[4, 32]. Microbes (including both bacteria and fungi) were more prevalent in  
287 HCB-females than in HCB-males (68.2 vs 13.6%,  $P < 0.001$ ; **Table S7**), whereas microbes were  
288 only slightly more prevalent in CKDB-females than in CKDB-males (51.1 vs 42.4%,  $P = 0.295$ ;  
289 **Table S8**). Microbes also were more prevalent in CKDB-males than in HCB-males (42.2 vs.  
290 13.6%,  $P = 0.014$ ; **Table S9**). In contrast, microbes were equally prevalent in CKDB-females and  
291 HCB-females (51.5 vs 68.2%,  $P = 0.173$ ; **Table S10**).

292 Only two identified genera and one unidentified genus were detected in HCB-males: the fungus  
293 *Cladosporium* was detected in one (4.5%), the bacterium *Curtobacterium* was detected in another  
294 (4.5%), and an unidentified genus was detected in a third (4.5%). In contrast, multiple genera were



295 detected in CKDB-males. The most prevalent genera were *Bacillus* [18.18% (11/66)],  
296 *Staphylococcus* [9.09% (6/66)], *Kocuria* [3.03% (2/66)], *Micrococcus* [3.03% (2/66)], and  
297 *Paenibacillus* [3.03% (2/66)]. The genus *Bacillus* was significantly more prevalent in the  
298 CKDB-males relative to HCB-males (Fisher's exact test,  $P=0.031$ ; **Figure 3A**).

299 Although the overall prevalence of microbes did not differ between HCB-females and  
300 CKDB-females, many genera differed (**Figure 3B**). The most prevalent in HCB-females were  
301 *Bacillus* [22.73% (5/22)], *Lactobacillus* [22.73% (5/22)], and *Herbaspirillum* [13.64% (3/22)],  
302 whereas the most prevalent in CKDB-females were *Bacillus* [15.15% (10/66)], *Escherichia* [7.58%  
303 (5/66)], and *Rothia spp.* [4.55% (3/66)]. The genera *Lactobacillus* and *Herbaspirillum* were  
304 significantly less prevalent in CKDB-females than in HCB-females (Fisher's exact test,  $P<0.05$ ;  
305 **Figure 3B**).

#### 306 **3.4 Altered genera in CKD was associated with demographics and renal function**

307 Because the bladder microbiome composition of CKDB-females and HCB-females differed, we  
308 used Pearson correlation analysis to determine whether any of the significantly different taxa (as  
309 determined by 16S rRNA gene sequencing) were associated with any demographic category or  
310 renal function. For CKDB-females, multiple associations were observed (**Figure 4A**). For  
311 example, *Escherichia-Shigella* was positively associated with CKDB-female serum creatinine  
312 ( $r=0.285$ ,  $P=0.020$ ). *Lactobacillus* was negatively associated with CKDB-female age and serum  
313 creatinine ( $r=-0.330$ ,  $P=0.007$  and  $r=-0.337$ ,  $P=0.006$ ; respectively), but positively associated with  
314 CKDB-female eGFR ( $r=0.251$ ,  $P=0.042$ ). *Bifidobacterium* was positively associated with  
315 CKDB-female disease duration ( $r=0.335$ ,  $P=0.006$ ). In contrast, significant associations were not  
316 observed for HCB-females ( $r<0.03$ ,  $P>0.05$ ; **Figure 4B**), with one exception: *Streptomyces* was  
317 positively associated with blood urea nitrogen ( $r=0.790$ ,  $P<0.001$ ).

#### 318 **3.5 Bacterial community altered in all stages of CKD patients**

319 For each CKD stage, we performed PCoA of Bray-Curtis Dissimilarity indices, comparing their  
320 bladder microbiomes to gender- and age-matched controls; these microbiomes differed  
321 significantly in stages 2-5 (PERMANOVA,  $FDR<0.05$ ), but not stage 1 (PERMANOVA,  
322  $FDR>0.05$ ; **Figure S3A**). These differences were primarily due to changes in composition, as only  
323 CKDB microbiomes from stages 3 and 5 were significantly richer than their respective HCB (as



324 measured by Chao 1; Wilcoxon rank-sum test,  $FDR < 0.05$ ) and the Shannon indices did not differ  
325 (**Figure S3B**).

### 326 **3.6 Altered bladder microbiome associated with altered serum cytokines in CKD patients**

327 To determine if associations exist between the bladder microbiome and serum cytokines, we  
328 first measured serum cytokines and then compared them to the bladder microbiome. Of the 48  
329 serum cytokines we assessed, 44 cytokines were detected. Of these, 23 cytokines differed  
330 significantly between the 66 CKD females and 22 female controls (Wilcoxon rank-sum test,  
331  $FDR < 0.001$ ). Some, such as IL-8, IL-18, IL-1 $\beta$  and TNF- $\alpha$  were increased in CKD females,  
332 whereas others, such as IL-9 and TNF- $\beta$  were decreased in CKD females (**Figure 5A**). To  
333 determine whether associations existed between serum cytokines and bladder microbial  
334 composition, we performed Pearson correlation analysis. Several taxa enriched in HCB-females  
335 were negatively associated with increased serum cytokines ( $r > 0.03$ ,  $P < 0.05$ ; **Figure 5B**). For  
336 example, the genera *Sphingobium* and *Streptomyces* were negatively associated with IL-18, IL-8,  
337 and/or IL-1 $\beta$ . In contrast, several taxa enriched in CKDB-females were positively associated with  
338 increased levels of serum cytokines ( $r > 0.03$ ,  $P < 0.05$ ; **Figure 5B**). For example, *Bifidobacterium*  
339 was positively associated with IL-2R $\alpha$ , and MIG ( $r > 0.03$ ,  $P < 0.05$ ), and IL-8 was positively  
340 associated with the members of Clostridia, including *Agathobacter*, *Blautia*, *Faecalibacterium*,  
341 *Subdoligranulum* ( $r > 0.03$ ,  $P < 0.05$ ). Intriguingly, the genus *Lactobacillus* was enriched in  
342 HCB-females but none of the correlations were statistically significant (**Figure 5B**).

### 343 **3.7 Alteration of microbiome not observed in feces**

344 To assess the gut-bladder axis in CKD, we assessed the fecal and bladder microbiomes of  
345 CKD-males ( $n=10$ ) to age-matched HC-males ( $n=10$ ) and CKD-females ( $n=22$ ) with age-matched  
346 HC-females ( $n=22$ ) who provided both fecal and catheterized urine samples. We observed no  
347 difference in gut microbiome compositions (PERMANOVA,  $FDR > 0.05$ ; **Figure 6A**) or alpha  
348 diversity (Wilcoxon rank-sum test,  $FDR > 0.05$ ; **Figure 6B**) between fecal samples from CKD  
349 males (CKDF-males) and fecal samples from HC males (HCF-males) or between fecal samples  
350 from CKD females (CKDF-females) and fecal samples from HC females (HCF-females). To test  
351 the hypothesis that gut-kidney leakage occurs in CKD patients, we first performed PCoA on the  
352 bladder and fecal microbiomes in CKD patients and controls; the bladder microbiomes differed

353 significantly from the corresponding fecal microbiomes for both CKD-males and females and  
354 their age-matched HC-controls (PERMANOVA, FDR<0.05; **Figures 6C-6F**). We then compared  
355 the Bray-Curtis dissimilarity between the bladder and gut microbiomes from either CKD  
356 males/females or HC males/females. These microbiomes tended to be less dissimilar in  
357 CKD-females than in HC-females (Wilcoxon rank-sum test, FDR<0.001), but not in the males  
358 (Wilcoxon rank-sum test, FDR>0.05; **Figure 6G**). In addition, the Bray-Curtis dissimilarity  
359 between the bladder and gut microbiomes from CKD females was slightly less than that from  
360 CKD males ( $0.965\pm 0.068$  vs.  $0.983\pm 0.048$ , Wilcoxon rank-sum test, FDR=0.089), while the  
361 Bray-Curtis dissimilarity between the bladder and fecal microbiomes from healthy females was  
362 almost equal to that from healthy males ( $0.998\pm 0.005$  vs.  $0.998\pm 0.004$ , Wilcoxon rank-sum test,  
363 FDR=0.472).

#### 364 **Discussion**

365 The role of a balanced intestinal microbiome in maintaining kidney function is widely  
366 recognized[2]; however, the role of the bladder microbiome in kidney functions remains  
367 understudied. This study is the first to reveal that CKD patients possess a distinct bladder  
368 microbiome, and that the bladder microbial profile is associated with unbalanced kidney function  
369 and dysregulated serum cytokine profiles.

370 First, we found that both male and female CKD patients had dysbiotic bladder microbiomes, as  
371 assessed by 16S rRNA gene sequencing. This dysbiosis may be associated with loss of kidney  
372 function, as the bladder microbiomes of CKD patients in stages 2-5 differed from those of controls.  
373 A similar phenomenon in the gut was described by Wu et al., who reported that the fecal  
374 microbiome could reflect the CKD stage[33].

375 We observed an increased microbial richness in CKD patients relative to controls and found that  
376 this increase was greater in females than in males, as assessed by both sequencing and EQUIC.  
377 Since population-based studies show that CKD affects more females than males[34], bladder  
378 dysbiosis in the context of CKD sex differences is worthy of future exploration.

379 One striking finding of this study is that CKD females' bladder microbiome was enriched for  
380 the genus *Escherichia/Shigella*, as assessed by both 16S rRNA gene sequencing and EQUIC. This  
381 genus was not associated with urinary leucocyte esterase or serum cytokine profile, but its

382 increase in CKD females was positively correlated to the level of serum creatinine, a kidney  
383 function estimator. Given that *Escherichia/Shigella* is the most commonly detected genus in  
384 UTI[29, 30], its increased prevalence at relatively high abundance in CKD females indicate that  
385 this potentially uropathogenic microbe should be a concern during treatment of CKD.

386 Another notable finding of this study is that both detection methods (sequencing and EQUIC)  
387 revealed a depletion of *Lactobacillus* in CKD females. Decreased *Lactobacillus* has been reported  
388 in patients with UTI[35], and may be a sign of an unhealthy bladder. Even though we did not  
389 observe an association between *Lactobacillus* and serum cytokines like previous urinary  
390 microbiome studies on interstitial cystitis and systemic lupus erythematosus suggested[20, 36],  
391 *Lactobacillus* was associated with the kidney function indicators. It was positively associated with  
392 eGFR and negatively associated with serum creatinine, indicating that *Lactobacillus* in the bladder  
393 may be a biomarker for kidney function. Although the effects of bladder *Lactobacillus* on kidney  
394 functions have never been reported, *Lactobacillus* oral supplementation in mouse models has been  
395 suggested to attenuate the loss of kidney function, in a process that involved inflammation  
396 pathways[37, 38]. Thus, *Lactobacillus* in the bladder might protect kidney function in females.

397 While decreased *Lactobacillus* in the vagina is a well-documented feature of older females,  
398 recent studies have shown this decrease to also be true of the bladder. Komesu et al. found that the  
399 relative abundance of *Lactobacillus* in catheterized urine had a strong negative relationship with  
400 age when study participants with mixed urinary incontinence and controls were assessed  
401 together[39]. Another study demonstrated that *Lactobacillus* in mid-stream voided urine was more  
402 common in pre-menopausal females comparing to post-menopausal ones[40]. In contrast, our  
403 study found a negative association between bladder *Lactobacillus* and age only in female CKD  
404 patients. This finding suggests that loss of kidney function, a sign of getting older[41], may be  
405 attributable to *Lactobacillus* depletion.

406 *Bifidobacterium* is widely advocated as a probiotic due to its potential beneficial effects[42].  
407 However, in our study, bladder *Bifidobacterium* was enriched in CKD females and positively  
408 associated with disease duration and MIG, a chemoattractant cytokine for activated T lymphocytes  
409 and tumor infiltrating T-lymphocytes[43], and an indication of an unhealthy kidney, e.g. kidney  
410 cancer or stones[44, 45]. Increased *Bifidobacterium* also has been reported in patients with kidney

411 stones[21]. *Bifidobacterium* has been reported in bladder infections and other diseases [46-48].

412 Therefore, it is unclear whether *Bifidobacterium* in the bladder serves as a probiotic or not.

413 The upregulation of IL-1 $\beta$ , IL-8, IL-18 and TNF- $\alpha$  in CKD patients have been reported[49-51].

414 As expected, all these cytokines were upregulated in the serum of CKD females, and almost all

415 were negatively associated with decreased *Sphingobium* in CKD female bladders. As *Sphingobium*

416 has been rarely reported, the roles of these associations remain to be examined in the future. It is

417 worth noting that half of the bacterial genera enriched in CKD females are members of the class

418 Clostridia, including *Agathobacter*, *Blautia*, *Faecalibacterium* and *Subdoligranulum*, and all were

419 positively linked to the increase of the level of IL-18 in patients. Some members of Clostridia,

420 including Clostridiales, Lachnospiraceae and Ruminococcaceae, have been reported to be enriched

421 in the voided urine of patients with chronic prostatitis[52]. It is reasonable to conclude that

422 Clostridia plays a pathogenic role in CKD females.

423 To explore the gut-kidney axis, we assessed the fecal and bladder microbiomes in

424 age-gender-matched CKD patients and controls. We only observed a statistical difference in the

425 bladder microbiome. Using the Bray-Curtis Dissimilarity Index, we compared the fecal and

426 bladder microbiomes and observed a statistically significant decrease in the female CKD patients

427 but not in the matched controls, supporting the hypothesis that “gut-leakage” may occur in CKD

428 females.

429 Our study has limitations. First, the number of CKD patients and age-gender-BMI matched

430 controls were unequal with a 3:1 patient:control ratio. Thus, there may exist additional

431 confounders that vary within the patients and controls[53]. However, kidney-age-related problems

432 are one of the most common health issues in elderly population[41], so it was difficult to recruit

433 healthy matched controls. Second, we only enrolled from a single institution which cannot

434 appropriately power the genetic profiles[54].

435 In summary, our study shows that the bladder microbiome of patients with CKD differs

436 significantly from that of the controls, especially in females. The bladder microbiomes of CKD

437 patients are richer (i.e., include more taxa) and many of those taxa are distinctly different in

438 prevalence and abundance between two groups. Both 16S rRNA gene sequencing and EQUIC

439 detected a significant increase of *Escherichia/Shigella* and a significant decline of *Lactobacillus* in

440 CKD females, and such alterations may be related to reduced kidney function. We observed  
441 associations between several bacterial genera in the bladders of CKD patients with several  
442 CKD-associated serum cytokines, suggesting that these genera might play a pathological role.  
443 Lastly, bladder dysbiosis was accompanied by “gut-leakage” in CKD females. Further studies are  
444 needed to investigate how the bladder microbiome modifies kidney function, inflammation and  
445 “gut leakage” using CKD animal models.

446 **Declarations**

447 **Ethics approval and Consent to participate**

448 The ethics committee of the Affiliated Wuxi Second Hospital of Nanjing Medical University  
449 approved the study (Ref. 2018051). Informed consent was provided by all subjects prior to sample  
450 collection.

451 **Consent for publication**

452 All authors consent to the publication of this manuscript.

453 **Availability of data and materials**

454 Raw data from 16S rRNA sequencing are available in the Sequence Read Archive under  
455 BioProject ID SRP360378 (<https://www.ncbi.nlm.nih.gov/bioproject/PRJNA807874>).

456 **Competing interests**

457 All authors declare that they have no competing interests.

458 **Funding**

459 Wuxi “Taihu Talents Program” Medical and Health High-level Talents Project  
460 (THRCJH20200901); Wuxi “key medical discipline construction” Municipal Clinical Medical  
461 Center (municipal public health center) Project (LCYXZX202103); Wuxi Technological Project  
462 (N20192047); Zhejiang Provincial Natural Science Foundation of China (LXR22H160001);  
463 National Natural Science Foundation of China (81874142 and 82073041).

464 Authors' contributions

465 Conceptualization: Fengping Liu, Alan J. Wolfe, Wei Chen, and Ninghan Feng; methodology:  
466 Fengping Liu, Jingjie Du, Qixiao Zhai, Hao Lin, Yifan Xu, Feng Yan, Yang Wang, Wei Guo,  
467 Zhenyi Xu, Jialin Hu, Peng Jiang, Chaoqun Gu, Jiayi Sheng, Lei Hu; software: Fengping Liu, and  
468 Jingjie Du; validation: Alan J. Wolfe; writing: Alan J. Wolfe, Fengping Liu, Jingjie Du, Yifeng  
469 Gu; supervision: Alan J. Wolfe; funding acquisition: Ninghan Feng; project administration:  
470 Fengping Liu, Jialin Hu, Lei Hu, Peng Jiang, Jiayi Sheng, Chaoqu Gu, Yang Wan, FengYan, Hao  
471 Lin, Shichao Wei.

472 **Acknowledgements**

473 We gratefully acknowledge the volunteers who participated in our study.

474 **Authors' information**

475 <sup>1</sup> Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China

476 <sup>2</sup> Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University  
477 Chicago, Maywood, Illinois, USA

478 <sup>3</sup> Department of Urology, Affiliated Wuxi No. 2 Hospital, Nanjing Medical University, Wuxi,  
479 Jiangsu, China

480 <sup>4</sup> Department of Nephrology, Affiliated Wuxi No. 2 Hospital, Nanjing Medical University, Wuxi,  
481 Jiangsu, China

482 <sup>5</sup> Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key  
483 Laboratory for Diagnosis and Treatment of Infectious Diseases, School of Medicine, The First  
484 Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China

485 <sup>6</sup> State Key Laboratory of Food Science and Technology and School of Food Science and  
486 Technology, Jiangnan University, Wuxi, Jiangsu, China

487

## 488 **Legends**

### 489 **Table 1 Demographics of urine donors of CKD patients and controls**

490 Pearson Chi-square or Fisher's exact test was used with categorical variables; Student's t test on normalized  
491 continuous variables was used.

492

493 **Figure 1** Bacterial composition, Venn, bacterial diversity, and phylum and genus composition in the urine from  
494 CKD patients and HC. **(A)** PCoA based on Bray-Curtis distances ASV level showed different microbial  
495 compositions between groups of CKDB-females and HCB-females, and between CKDB-males and HCB-males.  
496 The 95% confidence ellipse is drawn for each group. Permutational multivariate analysis of variance  
497 (PERMANOVA) was performed for statistical comparisons of samples in the two groups. *P* value was adjusted by  
498 the Benjamini and Hochberg false discovery rate (FDR). **(B)** Venn diagrams were made to compare the ASV  
499 composition within different groups. Each intersection of a number of areas represents the number of ASVs, which  
500 are present in all the intersecting areas. **(C)** Bacterial richness and diversity measured by Chao 1 and Shannon  
501 index were calculated at ASV level. Wilcoxon rank-sum test was performed and adjusted by Benjamini and  
502 Hochberg false discovery rate (FDR). \*\*\*,  $P_{\text{adj}} < 0.001$ . **(D)** Microbial profile at the phylum and genus level. Only  
503 the top 5 most abundant phylum and the top 15 most abundant genus are shown.

504 Abbreviations: CKDB-female: urine samples provided by females with CKD; CKDB-male: urine samples  
505 provided by males with CKD; HCB-female: urine samples provided by healthy females; HCB-male: urine  
506 samples provided by healthy males.

507

508 **Figure 2** Bacterial genera that were differentially abundant between CKD patients and controls. **(A)** Bacterial  
509 genera significantly decreased in CKDB-females comparing to those in HCB-females. **(B)** Bacterial genera  
510 significantly increased in CKDB-females comparing to those in HCB-females. P value was calculated using  
511 Wilcoxon rank-sum test and adjusted by Benjamini and Hochberg FDR. \*, FDR < 0.05; \*\*, FDR<0.01; and \*\*\*,  
512 FDR< 0.001.

513 Abbreviations: CKDB-female: urine samples provided by females with CKD; CKDB-male: urine samples  
514 provided by males with CKD; HCB-female: urine samples provided by healthy females; HCB-male: urine  
515 samples provided by healthy males.

516

517 **Figure 3** Comparisons of numbers of subjects with visible bacterial isolates between groups of patient and HC.  
518 Chi-square/Fisher's test was used, P values that are significant at 0.05. Bars represent the prevalence of isolates in  
519 each group.

520 Abbreviations: CKDB-female: urine samples provided by females with CKD; CKDB-male: urine samples  
521 provided by males with CKD; HCB-female: urine samples provided by healthy females; HCB-male: urine  
522 samples provided by healthy males.

523

524 **Figure 4** Bladder microbiome was associated with participants' demographics and kidney function estimators. **(A)**  
525 The heatmap depicted the association between the bacterial genera showing differed in CKDB-female and  
526 CKD-female's demographics and kidney function estimators. **(B)** The heatmap depicted the association between  
527 the bacterial genera showing differed in HCB-female and HC-female's demographics and kidney function  
528 estimators. Pearson correlation analysis was performed. The correlation of two variables with values of  $|r|>0.3$  and  
529  $P < 0.05$  are displayed. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; and \*\*\*,  $P < 0.001$ .

530

531 **Figure 5** Serum cytokines profiles in CKD females and their associations to urinary microbiome. **(A)** Serum  
532 cytokines increased and decreased in CKD females compared to controls. P value was calculated using Wilcoxon



533 rank-sum test and adjusted by Benjamini and Hochberg false discovery rate (FDR). **(B)** Pearson correlation  
534 analysis was performed on the bacterial genera and cytokines that differed between the CKD females and controls.  
535 The correlation of two variables with values of  $|r| > 0.3$  and  $P < 0.05$  are displayed. \*,  $P < 0.05$ ; \*\*,   
536  $P < 0.01$ ; and \*\*\*,  $P < 0.001$ .

537 Abbreviations: CKDB-female: urine samples provided by females with CKD; CKDS-female: serum samples  
538 provided by females with CKD; HCB-female: urine samples provided by healthy females; HCS-female: serum  
539 samples provided by healthy females.

540

541 **Figure 6** Comparisons of microbiomes in feces and urine in CKD males and females. **(A)** PCoA based on  
542 Bray-Curtis distances ASV level showed different microbial compositions between groups of CKDF-females and  
543 HCF-females, and between CKDF-males and HCF-males. The 95% confidence ellipse is drawn for each group.  
544 Permutational multivariate analysis of variance (PERMANOVA) was performed for statistical comparisons of  
545 samples in the two groups. *P* value was adjusted by the Benjamini and Hochberg false discovery rate (FDR). **(B)**  
546 Bacterial richness and diversity measured by Chao 1 and Shannon index were calculated at ASV level. Wilcoxon  
547 rank-sum test was performed and adjusted by Benjamini and Hochberg false discovery rate (FDR). **(C-F)** PCoA  
548 based on Bray-Curtis distances ASV level showed different microbial compositions between groups of  
549 CKDF-male and CKDB-male; between HCF-males and HCB-males; between CKDF-female and CKDB-female;  
550 between HCF-female and HCB-female. The 95% confidence ellipse is drawn for each group. Permutational  
551 multivariate analysis of variance (PERMANOVA) was performed for statistical comparisons of samples in the two  
552 groups. *P* value was adjusted by the Benjamini and Hochberg false discovery rate (FDR). **(G)** Comparisons of  
553 dissimilarity of Bray-Curtis between females and males' urine and feces in patients and controls group. Wilcoxon  
554 rank-sum test was performed and adjusted by Benjamini and Hochberg false discovery rate (FDR). \*\*,  $FDR <$   
555  $0.01$ .

556 Abbreviations: CKDF-female: fecal samples provided by females with CKD; CKDF-male: fecal samples provided  
557 by males with CKD; CKDB-female: urine samples provided by males with CKD; CKDB-male: urine samples  
558 provided by males with CKD; HCF-female: fecal samples provided by females with CKD; HCF-male: fecal  
559 samples provided by males with CKD; HCB-female: urine samples provided by healthy females; HCB-male: urine  
560 samples provided by healthy males.

561

562 **Table S1** Comparison of nutrient intake between CKD and HC cohort.

563 Student's *t* test on normalized continuous variables, and Wilcoxon rank-sum test on non-normal continuous  
564 variables.

565

566 **Tables S2** Comparison of bacterial phylum abundance between CKDB-male and HCB-male.

567 Wilcoxon rank-sum test was applied.

568 Abbreviations: CKDB-male: urine samples provided by males with CKD; HCB-male: urine samples provided by

569 healthy males.

570

571 **Table S3** Comparison of bacterial phylum abundance between CKDB-female and HCB-female.

572 Wilcoxon rank-sum test was applied.

573 Abbreviations: CKDB-female: urine samples provided by females with CKD; HCB-female: urine samples

574 provided by healthy females.

575

576 **Table S4** Comparison of bacterial genus abundance between CKDB-male and HCB-male.

577 Wilcoxon rank-sum test was applied.

578 Abbreviations: CKDB-male: urine samples provided by males with CKD; HCB-male: urine samples provided by

579 healthy males.

580

581 **Table S5** Comparison of bacterial genus abundance between CKDB-female and HCB-female.

582 Wilcoxon rank-sum test was applied.

583 Abbreviations: CKDB-female: urine samples provided by females with CKD; HCB-female: urine samples

584 provided by healthy females.

585

586 **Table S6** Bacteria identified using EQUIC.

587 Abbreviations: CKDB-male: urine samples provided by males with CKD; CKDB-female: urine samples provided

588 by females with CKD; HCB-male: urine samples provided by healthy males; HCB-female: urine samples provided

589 by healthy females.

590

591 **Table S7** Comparisons of samples with visible cultures between HCB-male and HCB-female. Pearson Chi-square  
592 or Fisher's exact test was used

593 Abbreviations: CKDB-male: urine samples provided by males with CKD; HCB-male: urine samples provided by  
594 healthy males.

595

596 **Table S8** Comparisons of samples with visible cultures between HCB-male and HCB-female. Pearson Chi-square  
597 or Fisher's exact test was used.

598 Abbreviations: CKDB-female: urine samples provided by females with CKD; HCB-female: urine samples  
599 provided by healthy females.

600

601 **Table S9** Comparison of samples with visible cultures between CKDB-male and HCB-male.

602 Pearson Chi-square or Fisher's exact test was used.

603 Abbreviations: CKDB-male: bladder urine samples provided by males with CKD; HCB-male: bladder urine  
604 samples provided by healthy males.

605

606 **Table S10** Comparison of samples with visible cultures between CKDB-female and HCB-female.

607 Pearson Chi-square or Fisher's exact test was used.

608 Abbreviations: CKDB-female: bladder urine samples provided by females with CKD; HCB-female: bladder urine  
609 samples provided by healthy females.

610

611 **Figure S1** Stud design.

612 Participants enrollment and study procedures.

613 Abbreviations: CKDB: urine samples provided by patients with CKD; HCB: urine samples provided by healthy  
614 controls; CKDF: fecal samples provided by patients with CKD; HCF: fecal samples provided by healthy controls;  
615 CKDS: serum samples provided by CKD patient; HCS: serum samples provided by healthy controls.

616

617 **Figure S2** Medication usages on urinary microbiome.

618 **(A)** Comparison of urinary microbiome between antihypertensive agent users and non-users; **(B)** Comparison of  
619 urinary microbiome between glucocorticoid agent users and non-users; **(C)** Comparison of urinary microbiome

620 between hypoglycemic agent users and non-users; **(D)** Comparison of urinary microbiome between hypolipidemic  
621 agent users and non-users. Permutational multivariate analysis of variance (PERMANOVA) was performed for  
622 statistical comparisons of samples in the two groups. *P* value was adjusted by the Benjamini and Hochberg false  
623 discovery rate (FDR).

624

625 **Figure S3** Urinary microbiome in various CKD stages.

626 **(A)** Comparisons of microbial community between patients in CKD stage1-stage5 and controls. Permutational  
627 multivariate analysis of variance (PERMANOVA) was performed for statistical comparisons of samples in the two  
628 groups. *P* value was adjusted by the Benjamini and Hochberg false discovery rate (FDR). **(B)** Comparisons of  
629 microbial richness and diversity between patients in CKD stage1-stage5 and controls. Wilcoxon rank-sum test was  
630 performed and adjusted by Benjamini and Hochberg false discovery rate (FDR).

631


## 632 **References**

- 633 1. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and  
634 national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global  
635 Burden of Disease Study 2017. *The Lancet*. 2020;395(10225):709-33.
- 636 2. Meijers B, Evenepoel P, Anders HJ. Intestinal microbiome and fitness in kidney disease. *Nat Rev*  
637 *Nephrol*. 2019;15(9):531-45.
- 638 3. Shah NB, Allegretti AS, Nigwekar SU, Kalim S, Zhao S, Lelouvier B, et al. Blood Microbiome  
639 Profile in CKD : A Pilot Study. *Clin J Am Soc Nephrol*. 2019;14(5):692-701.
- 640 4. Hilt EE, Mckinley K, Pearce MM, Rosenfeld AB, Zilliox MJ, Mueller ER, et al. Urine is not  
641 sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult  
642 female bladder. *J Clin Microbiol*. 2014;52(3):871-6.
- 643 5. Wolfe AJ, Toh E, Shibata N, Rong R, Kenton K, Fitzgerald M, et al. Evidence of uncultivated  
644 bacteria in the adult female bladder. *J Clin Microbiol*. 2012;50(4):1376-83.
- 645 6. Pearce MM, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C, et al. The female  
646 urinary microbiome: a comparison of women with and without urgency urinary incontinence.  
647 *Mbio*. 2014;5(4):e1214-83.
- 648 7. Liu F, Du J, Zhai Q, Hu J, Miller AW, Ren T, et al. The Bladder Microbiome, Metabolome,  
649 Cytokines, and Phenotypes in Patients with Systemic Lupus Erythematosus. *Microbiol Spectr*.  
650 2022:e21222.
- 651 8. Roth RS, Liden M, Huttner A. The urobiome in men and women: a clinical review. *Clin*  
652 *Microbiol Infect*. 2022.
- 653 9. Kachroo N, Lange D, Penniston KL, Stern J, Tasian G, Bajic P, et al. Meta-analysis of Clinical  
654 Microbiome Studies in Urolithiasis Reveal Age, Stone Composition, and Study Location as the  
655 Predominant Factors in Urolithiasis-Associated Microbiome Composition. *Mbio*.






- 656 2021;12(4):e200721.
- 657 10. Vaughan MH, Mao J, Karstens LA, Ma L, Amundsen CL, Schmader KE, et al. The Urinary  
658 Microbiome in Postmenopausal Women with Recurrent Urinary Tract Infections. *J Urol*.  
659 2021;206(5):1222-31.
- 660 11. Wu P, Zhang G, Zhao J, Chen J, Chen Y, Huang W, et al. Profiling the Urinary Microbiota in  
661 Male Patients With Bladder Cancer in China. *Front Cell Infect Microbiol*. 2018;8:167.
- 662 12. Kramer H, Kuffel G, Thomas-White K, Wolfe AJ, Vellanki K, Leehey DJ, et al. Diversity of the  
663 midstream urine microbiome in adults with chronic kidney disease. *Int Urol Nephrol*.  
664 2018;50(6):1123-30.
- 665 13. Frimodt-Møller N. The urine microbiome &#x2013; Contamination or a novel paradigm?  
666 *Ebiomedicine*. 2019;44:20-1.
- 667 14. Brubaker L, Gourdine JF, Siddiqui NY, Holland A, Halverson T, Limeria R, et al. Forming  
668 Consensus To Advance Urobiome Research. *Msystems*. 2021;6(4):e137120.
- 669 15. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P. Cytokine dysregulation in chronic kidney  
670 disease: how can we treat it? *Blood Purif*. 2008;26(3):291-9.
- 671 16. Amdur RL, Feldman HI, Gupta J, Yang W, Kanetsky P, Shlipak M, et al. Inflammation and  
672 Progression of CKD: The CRIC Study. *Clin J Am Soc Nephrol*. 2016;11(9):1546-56.
- 673 17. Salguero MV, Al Obaide MAI, Singh R, Siepmann T, Vasylyeva TL. Dysbiosis of  
674 Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates  
675 inflammation in type 2 diabetic patients with chronic kidney disease. *Exp Ther Med*.  
676 2019;18(5):3461-9.
- 677 18. Linh HT, Iwata Y, Senda Y, Sakai-Takemori Y, Nakade Y, Oshima M, et al. Intestinal Bacterial  
678 Translocation Contributes to Diabetic Kidney Disease. *J Am Soc Nephrol*. 2022;33(6):1105-19.
- 679 19. Tao S, Li L, Li L, Liu Y, Ren Q, Shi M, et al. Understanding the gut-kidney axis among  
680 biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis  
681 of the gut microbiota composition. *Acta Diabetol*. 2019;56(5):581-92.
- 682 20. Liu F, Du J, Zhai Q, Hu J, Miller AW, Ren T, et al. The Bladder Microbiome, Metabolome,  
683 Cytokines, and Phenotypes in Patients with Systemic Lupus Erythematosus. *Microbiol Spectr*.  
684 2022:e21222.
- 685 21. Liu F, Zhang N, Jiang P, Zhai Q, Li C, Yu D, et al. Characteristics of the urinary microbiome in  
686 kidney stone patients with hypertension. *J Transl Med*. 2020;18(1):130.
- 687 22. Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Fernandez-Fernandez  
688 B, Martin-Cleary C, et al. Clarifying the concept of chronic kidney disease for non-nephrologists.  
689 *Clin Kidney J*. 2019;12(2):258-61.
- 690 23. Fengping L, Jingjie D, Qixiao Z, Jialin H, Aaron W M, Tianli R, et al. The bladder microbiome,  
691 metabolome, cytokines, and phenotypes in patients with systemic lupus erythematosus.  
692 *Mycobiology Spectrum*. 2022.
- 693 24. Hilt EE, Mckinley K, Pearce MM, Rosenfeld AB, Zilliox MJ, Mueller ER, et al. Urine is not  
694 sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult  
695 female bladder. *J Clin Microbiol*. 2014;52(3):871-6.
- 696 25. Guo X, Kim J, Nam H, Park S, Kim J. Screening lactic acid bacteria from swine origins for  
697 multistrain probiotics based on in vitro functional properties. *Anaerobe*. 2010;16(4):321-6.
- 698 26. Mesureur J, Arend S, Celliere B, Courault P, Cotte-Pattat PJ, Totty H, et al. A MALDI-TOF MS  
699 database with broad genus coverage for species-level identification of *Brucella*. *PLoS Negl Trop*

- 700 Dis. 2018;12(10):e6874.
- 701 27. Pohl HG, Groah SL, Perez-Losada M, Ljungberg I, Sprague BM, Chandal N, et al. The Urine  
702 Microbiome of Healthy Men and Women Differs by Urine Collection Method. *Int Neurourol J*.  
703 2020;24(1):41-51.
- 704 28. Gottschick C, Deng ZL, Vital M, Masur C, Abels C, Pieper DH, et al. The urinary microbiota of  
705 men and women and its changes in women during bacterial vaginosis and antibiotic treatment.  
706 *Microbiome*. 2017;5(1):99.
- 707 29. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology,  
708 mechanisms of infection and treatment options. *Nat Rev Microbiol*. 2015;13(5):269-84.
- 709 30. Huttner A, Hatz C, van den Dobbelen G, Abbanat D, Hornacek A, Frolich R, et al. Safety,  
710 immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic  
711 *Escherichia coli* in women with a history of recurrent urinary tract infection: a randomised,  
712 single-blind, placebo-controlled phase 1b trial. *Lancet Infect Dis*. 2017;17(5):528-37.
- 713 31. Song CH, Kim YH, Naskar M, Hayes BW, Abraham MA, Noh JH, et al. *Lactobacillus crispatus*  
714 Limits Bladder Uropathogenic *E. coli* Infection by Triggering a Host Type I Interferon  
715 Response. *Proc Natl Acad Sci U S A*. 2022;119(33):e2117904119.
- 716 32. Price TK, Dune T, Hilt EE, Thomas-White KJ, Kliethermes S, Brincat C, et al. The Clinical Urine  
717 Culture: Enhanced Techniques Improve Detection of Clinically Relevant Microorganisms. *J Clin*  
718 *Microbiol*. 2016;54(5):1216-22.
- 719 33. Wu IW, Gao SS, Chou HC, Yang HY, Chang LC, Kuo YL, et al. Integrative metagenomic and  
720 metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney  
721 disease. *Theranostics*. 2020;10(12):5398-411.
- 722 34. Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology  
723 and outcomes of chronic kidney disease. *Nat Rev Nephrol*. 2018;14(3):151-64.
- 724 35. Pearce MM, Zilliox MJ, Rosenfeld AB, Thomas-White KJ, Richter HE, Nager CW, et al. The  
725 female urinary microbiome in urgency urinary incontinence. *Am J Obstet Gynecol*.  
726 2015;213(3):341-7.
- 727 36. Abernethy MG, Rosenfeld A, White JR, Mueller MG, Lewicky-Gaupp C, Kenton K. Urinary  
728 Microbiome and Cytokine Levels in Women With Interstitial Cystitis. *Obstet Gynecol*.  
729 2017;129(3):500-6.
- 730 37. Kim H, Nam BY, Park J, Song S, Kim WK, Lee K, et al. *Lactobacillus acidophilus* KBL409  
731 Reduces Kidney Fibrosis via Immune Modulatory Effects in Mice with Chronic Kidney Disease.  
732 *Mol Nutr Food Res*. 2022:e2101105.
- 733 38. Tungsanga S, Katavetin P, Panpetch W, Udompornpitak K, Saisorn W, Praditpornsilpa K, et al.  
734 *Lactobacillus rhamnosus* L34 attenuates chronic kidney disease progression in a 5/6  
735 nephrectomy mouse model through the excretion of anti-inflammatory molecules. *Nephrol Dial*  
736 *Transplant*. 2022;37(8):1429-42.
- 737 39. Komesu YM, Dinwiddie DL, Richter HE, Lukacz ES, Sung VW, Siddiqui NY, et al. Defining the  
738 relationship between vaginal and urinary microbiomes. *Am J Obstet Gynecol*. 2020;222(2):151-4.
- 739 40. Curtiss N, Balachandran A, Krska L, Peppiatt-Wildman C, Wildman S, Duckett J. Age,  
740 menopausal status and the bladder microbiome. *Eur J Obstet Gynecol Reprod Biol*.  
741 2018;228:126-9.
- 742 41. Ellam T, Twohig H, Khwaja A. Chronic kidney disease in elderly people: disease or disease label?  
743 *BMJ*. 2016;352:h6559.

- 744 42. Ming J, Yu X, Xu X, Wang L, Ding C, Wang Z, et al. Effectiveness and safety of Bifidobacterium  
745 and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a  
746 multi-center, double-blind, randomized, parallel-controlled study. *Genome Med.*  
747 2021;13(1):125.
- 748 43. Whiting D, Hsieh G, Yun JJ, Banerji A, Yao W, Fishbein MC, et al. Chemokine monokine  
749 induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and  
750 effector cytokine production. *J Immunol.* 2004;172(12):7417-24.
- 751 44. Lee MH, Laajala E, Kreutzman A, Jarvinen P, Nisen H, Mirtti T, et al. The tumor and plasma  
752 cytokine profiles of renal cell carcinoma patients. *Sci Rep.* 2022;12(1):13416.
- 753 45. Suen JL, Liu CC, Lin YS, Tsai YF, Juo SH, Chou YH. Urinary chemokines/cytokines are  
754 elevated in patients with urolithiasis. *Urol Res.* 2010;38(2):81-7.
- 755 46. Mahlen SD, Clarridge JR. Site and clinical significance of *Alloscardovia omnicolens* and  
756 *Bifidobacterium* species isolated in the clinical laboratory. *J Clin Microbiol.*  
757 2009;47(10):3289-93.
- 758 47. Pathak P, Trilligan C, Rapose A. *Bifidobacterium*--friend or foe? A case of urinary tract infection  
759 with *Bifidobacterium* species. *BMJ Case Rep.* 2014;2014.
- 760 48. Bhaskar MM, Sistla S, Kumaravel S. A case of pyometrocolpos with *Bifidobacterium* species.  
761 *Anaerobe.* 2017;44:48-50.
- 762 49. Komada T, Muruve DA. The role of inflammasomes in kidney disease. *Nat Rev Nephrol.*  
763 2019;15(8):501-20.
- 764 50. Vianna HR, Soares CM, Silveira KD, Elmiro GS, Mendes PM, de Sousa TM, et al. Cytokines in  
765 chronic kidney disease: potential link of MCP-1 and dyslipidemia in glomerular diseases.  
766 *Pediatr Nephrol.* 2013;28(3):463-9.
- 767 51. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, et al. Association between  
768 albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. *Clin J Am*  
769 *Soc Nephrol.* 2012;7(12):1938-46.
- 770 52. Shoskes D, Altemus J, Polackwich A, Tucky B, Wang H, Eng C. The Urinary Microbiome  
771 Differs Significantly Between Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome  
772 and Controls as Well as Between Patients With Different Clinical Phenotypes. *Urology.*  
773 2016;92:26-32.
- 774 53. Zhu Z, Satten GA, Mitchell C, Hu YJ. Constraining PERMANOVA and LDM to within-set  
775 comparisons by projection improves the efficiency of analyses of matched sets of microbiome  
776 data. *Microbiome.* 2021;9(1):133.
- 777 54. McWilliams R, Hoover-Fong J, Hamosh A, Beck S, Beaty T, Cutting G. Problematic variation in  
778 local institutional review of a multicenter genetic epidemiology study. *JAMA.*  
779 2003;290(3):360-6.
- 780




HCB-male vs HCB-female  $R^2=0.077$   $FDR=0.002$   
 CKDB-male vs CKDB-female  $R^2=0.017$   $FDR=0.016$   
 CKDB-male vs HCB-male  $R^2=0.033$   $FDR=0.001$   
 CKDB-female vs HCB-female  $R^2=0.072$   $FDR<0.001$








A




B






**A****B**

A



B







# Objectives

# Process


Is dysbiotic bladder microbiome associated with CKD?



Which microbiome can predict CKD? Bladder or feces?








Is dysbiotic bladder microbiome associated with serum cytokines?




## Abbreviations

CKDB: CKD patient's bladder; HCB: healthy control's bladder; CKDF: CKD patient's feces; HCF: healthy control's feces; CKDS: CKD patient's serum; HCS: healthy control's serum


**A****B****C****D**

**A**


$R^2=0.124$   $FDR=0.064$




$R^2=0.051$   $FDR=0.001$



$R^2=0.108$   $FDR=0.001$



$R^2=0.099$   $FDR=0.001$



$R^2=0.088$   $FDR=0.001$

**B**